
Indivior’s Gilles Picard charts a path to greater patient access and new therapies

Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna

The healthcare business doesn’t meet GSK’s criteria for returns, says Walmsley

The former RB pharma unit hopes for sales in the $1bn region

The RB spin out will appeal against the ruling

Titan and Braeburn's Probuphine is first implant of its kind to win US approval

Probuphine has been developed by Titan Pharma and partner Braeburn Pharma

Demerged business will focus on opioid dependence product Suboxone

Will separate prescription and consumer health businesses